It cannot legally be marketed as a drug or medicine
Neither BPC-157 nor TB-500 has demonstrated significant adverse effects in published research at standard doses
Minor side effects & safety profile While AOD 9604 appears to have a favorable tolerability profile in early trials, there are still relevant caution points: Reported/mild side-effects Injection-site reactions: redness, swelling, itching, mild pain
AOD-9604 offers a distinct, IGF-1-independent lipolysis mechanism worth studying in its own right
Reconstitution Solution ensures multiple, sterile withdrawals from the vial without the risk of bacterial contamination, ideal for researchers handling peptides and other reagents
Expired vials increase risks for dangerous bacterial contamination